|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�Դ������� |
|
���� |
| ��������������� | |
|
��� |
|
�۳��� |
| PubMed | |
|
Article by |
|
Article by |
�Դ������������о���չ
��ΰ��, �۳���
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
������Ԥ���Ϳ����Դ��������Ĺؼ���ʩ���������ײ���������,Ŀǰ�����ٴ�Ӧ�õ������Դ�����������,���������Դ�������������о�ȡ���˲��ٽ�չ,���������ѽ����ٴ�����Ρ��������ܲ����硢ɳ����ԭ�����硢������������������ͷ������������о�,�������ٴ�������½�չ��
[2] Gulati S,Ngampasutadol J,Yamasaki R,et al.Strategies for mimicking Neisserial saccharide epitopes as vaccines.Int Rev lmmunol,2001,20(2):229-250.
[3] Turner PC,Thomas CE,Stojiljkovic I,et al.Neisserial TonB-dependent outer-membrane proteins:detection,regulation and distribution of three putative candidates identified from the genome sequences.Microbiology,2001,147(Pt5):1277-1290.
[4] Russell MW,Hedges SR,Wu HY,et al.Mucosal immunity in the genital tract:prospects for vaccines against sexually transmitted diseases-a review.Am J Reprod Immunol,1999,42(1):58-63.
[5] lgietseme JU,Black CM,Caldwell HD.Chlamydia vaccines:strategies and status.BioDrugs,2002,16(1):19-35.
[6] Stephens RS.Chlamydial genomics and vaccine antigen discovery.J Infect Dis,2000,181(Suppl 3):S521-S523.
[7] Igietseme JU,Ananaba GA,Bolier J,et al.Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Thl induction:potential for cellular vaccine development.J Immunol,2000,164(8):4212-4219.
[8] Eko FO,Lubitz W,MeMillan L,et al.Recombinant Vibrio eholerae ghosts as a delivery vehicle for vaccinating against Chlamydia traehomatis.Vaccine,2003,21(15):1694-1703.
[9] Igietseme JU,Murdin A.Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes.Infect Immun,2000,68(12):6798-6806.
[10] Brunham RC.Prospects for a chlamydial vaccine.In:Murray BE,eds.Program and abstracts of the 42nd Interseience Conference on Antimicrobial Agents and Chemotherapy,42nd ICAAC,San Diego,2002,Washington,DC:ASM Press,2002:A1552.
[11] Koelle DM,Corey L.Recent progress in herpes simplex virus immunobiology and vaccine research.Clin Microbiol Rev,2003,16(1):96-113.
[12] Stanberry LR,Cunningham AL,Mindel A,et al.Prospects for Control of herpes simplex virus disease through immunization.Clin Infect Dis,2000,30(3):549-566.
[13] Corey L,Langenberg AG,Ashley R,et al.Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection:two randomized controlled trials.Chiron HSV Vaccine Study Group.JAMA,1999,282(4):331-340.
[14] Stanberry LR,Spruance SL,Cunningham AL,et al.Glycoprotein-Dadjuvant vaccine to prevent genital herpes.N Engl J Med,2002,347(21):1652-1661.
[15] Stanberry L.HSV vaccines.In:Murray BE,eds.Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy,42nd ICAAC,San Diego,2002,Washington,DC:ASM Press,2002:A1554.
[16] Casanova G,Cancela R,Alonzo L,et al.A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections.Cutis,2002,70(4):235-239.
[17] Morrison LA.Vaccines against genital herpes:progress and limitations.Drugs,2002,62(8):1119-1129.
[18] Berry JM,Palefsky JM.A review of human papillomavirus vaccines:from basic science to clinical trials.Front Biosci,2003,8:S333-S345.
[19] Frazer I.Vaccines for papillomavirus infection.Virus Res,2002,89(2):271-274.
[20] Tobery TW,Smith JF,Kuklin N,et al.Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques.Vaccine,2003,21(13-14):1539-1547.
[21] Moniz M,Ling M,Hung CF,et al.HPV DNA vaccines.Front Biosci,2003,8:D55-68.
[22] Koutsky LK.HPV vaccines.In:Murray BE,eds.Program and abstracts of the 42nd Interseience Conference on Antimierobial Agents and Chemotherapy,42nd ICAAC,San Diego,2002,Washington,DC:ASM Press,2002:A1553.
[23] Koutsky LA,Ault KA,Wheeler CM,et al.A controlled trial of a human papillomavirus type 16 vaccine.N Engl J Med,2002,347(21):1645-1651.
[24] Billich A.HPV vaccine Medlmmune/GlaxoSmithKline.Curr Opin Investig Drugs,2003,4(2):210-213.